Evidence map›Paper›PMID 42015266›Full record

ArticleJournal of translational medicine2026

Gypenosides inhibit melanoma proliferation, migration and enhance the anti-tumor immunity of CD8

Yue Yin, Wenjing Lai, Changpeng Hu, Huyue Zhou, Yali Liu, Yafeng Liu, Min Yang, Kan He, Guobing Li

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yue Yin *Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, 130021, China.
Wenjing Lai *Department of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China.
Changpeng HuDepartment of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China.
Huyue ZhouDepartment of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China.
Yali LiuDepartment of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China.
Yafeng LiuDepartment of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China.
Min YangDepartment of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China.
Kan HeDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, 130021, China. hek@jlu.edu.cn.
Guobing LiDepartment of Pharmacy, The Second Affiliated Hospital of Third Military, Medical University, Chongqing, 400037, China. guobingl@tmmu.edu.cn.ORCID 0000-0003-4113-5641

Funding

Chongqing Bayu Qihuang Young Scholar Program Chongqing Bayu Qihuang Young Scholar ProgramChongqing Bayu Young Scholar Program S2023027National Natural Science Foundation of China 82404930
6 · The paper itself

Abstract

backgroundMelanoma is a highly aggressive cancer that often creates a profoundly immunosuppressive tumor microenvironment and tends to invade and metastasize early in the disease process. Gypenosides have been reported to exhibit anti-melanoma activity, yet its underlying mechanisms remain incompletely understood. The objective is to assess the role of gypenosides in anti-melanoma and to further investigate its pharmacological effects.

methodsA systematic evaluation of the anti-melanoma efficacy and safety of gypenosides was established by in vitro and in vivo experiments. Transcriptome sequencing was used to screen potential molecular targets, and co-culture and flow cytometry were applied to explore the effects of gypenosides, aiming to elucidate the underlying mechanisms.

resultsBoth in vitro and in vivo experiments have observed that gypenosides, as well as their active monomers gypenoside-XLIX and gypenoside-LI, significantly inhibit melanoma cell proliferation by inducing G0/G1 cell cycle arrest, and inhibit migration through downregulating MMP2/MMP9. RNA-sequencing combined with gene expression perturbation identified ETV5 as the key mediator of the anti-tumor activity of gypenosides. Additionally, gypenosides downregulate the expression of PD-L1 via ETV5 in tumor cells, thereby promoting the activation of tumor-infiltrating CD8+ T cells and enhancing CD8+ T cell-mediated anti-melanoma immunity. In mouse tumor models, gypenosides demonstrate potent efficacy in inhibiting melanoma growth and lung metastasis, and exhibit a favorable safety profile.

conclusionGypenosides and its active monomers gypenoside-XLIX and gypenoside-LI inhibit the proliferation and migration of melanoma, suppress the upregulation of ETV5-mediated increase in PD-L1 expression, and enhance the anti-tumor immunity of CD8+ T cells and promote the release of cytokines. These findings indicate that gypenosides may have valuable applications in the clinical treatment of melanoma and provide a useful theoretical basis.

Indexed as

B7-H1 AntigenCD8-Positive T-LymphocytesCell MovementDNA-Binding ProteinsMelanomaSignal TransductionTranscription FactorsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGynostemmaHumansMice, Inbred C57BLPlant ExtractsB7-H1 AntigenDNA-Binding ProteinsgypenosidePlant ExtractsTranscription FactorsAnti-tumor immunityETV5GypenosidesMelanomaPD-L1

Identifiers

PMID42015266
PMCPMC13238025

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.